Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102506 | 1.00 | SCD (0.43) | SCDTRPV1GPR52TLR7ALDH1A1 | |
| SCHEMBL1240264 | 0.92 | ALDH1A1 (0.42) | TRPV1GPR52TLR7ALDH1A1LMNA | |
| SCHEMBL1240267 | 0.92 | ALDH1A1 (0.42) | TRPV1GPR52TLR7ALDH1A1LMNA | |
| SCHEMBL1241275 | 0.90 | CCR2 (0.42) | TRPV1TLR7ALDH1A1LMNAVNN1 | |
| SCHEMBL1241273 | 0.90 | CCR2 (0.42) | TRPV1TLR7ALDH1A1LMNAVNN1 | |
| SCHEMBL1241570 | 0.89 | HRH3 (0.46) | SCDTRPV1LMNAVNN1HRH3 | |
| SCHEMBL1241568 | 0.89 | HRH3 (0.46) | SCDTRPV1LMNAVNN1HRH3 | |
| SCHEMBL9100118 | 0.89 | BRAF (0.45) | LMNA | |
| SCHEMBL9100122 | 0.89 | BRAF (0.45) | LMNA | |
| SCHEMBL1241560 | 0.88 | SORT1 (0.43) | SCDTRPV1TLR7ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | SCD 1954/4885TRPV1 13/4885GPR52 2295/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | SCD 1954/4885TRPV1 13/4885GPR52 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.